Consolidation treatment with an anti-PD-L1 antibody, durvalumab, following concurrent chemoradiotherapy has become a new standard of care for locally advanced non-small cell lung cancer [19]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.